Acticor Biotech (France) Today
| ALACT Stock | EUR 0.25 0.00 0.00% |
Performance0 of 100
| Odds Of DistressLess than 25
|
Acticor Biotech is selling at 0.25 as of the 31st of January 2025; that is No Change since the beginning of the trading day. The stock's last reported lowest price was 0.25. Acticor Biotech has about a 25 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 3rd of September 2024 and ending today, the 31st of January 2025. Click here to learn more.
Acticor Biotech SAS, a clinical stage biopharmaceutical company, develops drugs for the treatment of acute phase of thrombotic diseases. The company was founded in 2013 and is headquartered in Paris, France. ACTIPLAY is traded on Paris Stock Exchange in France. The company has 10.52 M outstanding shares. More on Acticor Biotech SAS
Moving together with Acticor Stock
Moving against Acticor Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Acticor Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Acticor Biotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Acticor Biotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | Julien Parrou |
| Thematic Idea | IT (View all Themes) |
| Business Concentration | IT, Communication Services, Media, Advertising Agencies, Communication Services, Computing (View all Sectors) |
Acticor Biotech SAS (ALACT) is traded on Euronext Paris in France and employs 25 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 95.69 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Acticor Biotech's market, we take the total number of its shares issued and multiply it by Acticor Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Acticor Biotech SAS operates under Media sector and is part of Communication Services industry. The entity has 10.52 M outstanding shares.
Acticor Biotech SAS has accumulated about 571.18 K in cash with (13.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.17.
Check Acticor Biotech Probability Of Bankruptcy
Acticor Biotech SAS Risk Profiles
Although Acticor Biotech's alpha and beta are two of the key measurements used to evaluate Acticor Biotech's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.68 | |||
| Standard Deviation | 7.42 | |||
| Variance | 55.03 | |||
| Risk Adjusted Performance | (0.05) |
Acticor Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Acticor Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Cryptocurrency Center Now
Cryptocurrency CenterBuild and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
| All Next | Launch Module |
Acticor Biotech Corporate Directors
| Patrice Coffe | Administrative and Financial Director, Member of the Board | Profile | |
| Hugues Duboscq | Director - Permanent Representative of Saint-Florentin Participations | Profile | |
| Jerome Leleu | Director | Profile | |
| Frederic Bartoli | Director - Representative of Chorus | Profile |
Additional Tools for Acticor Stock Analysis
When running Acticor Biotech's price analysis, check to measure Acticor Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acticor Biotech is operating at the current time. Most of Acticor Biotech's value examination focuses on studying past and present price action to predict the probability of Acticor Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acticor Biotech's price. Additionally, you may evaluate how the addition of Acticor Biotech to your portfolios can decrease your overall portfolio volatility.